Chemoinformaics analysis of (1S)-((2R,4S,5R)-5-Ethylquinuclidin-2-yl)(quinolin-4-yl)methanol
| Molecular Weight | 296.414 | nRot | 3 |
| Heavy Atom Molecular Weight | 272.222 | nRig | 20 |
| Exact Molecular Weight | 296.189 | nRing | 5 |
| Solubility: LogS | -2.546 | nHRing | 4 |
| Solubility: LogP | 3.229 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 46 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 1 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 3 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 10 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 11 |
| nHA | 3 | APOL | 50.735 |
| nHD | 1 | BPOL | 26.927 |
| QED | 0.943 |
| Synth | 4.331 |
| Natural Product Likeliness | 0.631 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.987 |
| Pgp-sub | 0.999 |
| HIA | 0.005 |
| CACO-2 | -4.701 |
| MDCK | 0.0000166 |
| BBB | 0.739 |
| PPB | 0.61535 |
| VDSS | 3.898 |
| FU | 0.400826 |
| CYP1A2-inh | 0.238 |
| CYP1A2-sub | 0.894 |
| CYP2c19-inh | 0.196 |
| CYP2c19-sub | 0.857 |
| CYP2c9-inh | 0.057 |
| CYP2c9-sub | 0.215 |
| CYP2d6-inh | 0.947 |
| CYP2d6-sub | 0.893 |
| CYP3a4-inh | 0.146 |
| CYP3a4-sub | 0.768 |
| CL | 7.25 |
| T12 | 0.391 |
| hERG | 0.685 |
| Ames | 0.064 |
| ROA | 0.782 |
| SkinSen | 0.44 |
| Carcinogencity | 0.362 |
| EI | 0.128 |
| Respiratory | 0.966 |
| NR-Aromatase | 0.026 |
| Antiviral | No |
| Prediction | 0.527246 |